Ann: Change in substantial holding, page-35

I think anyone expecting an update on the Type A meeting today needs to temper their expectations …. It’s been less than 30 days and we know the FDA have pushed anything Mesoblast in the past right out to the last day and of course the written correspondence confirming meeting decisions can take up to another 30 days …. I can’t see SI saying much at all about this other than it has been requested

I do however expect some substantial information on at least the CLBP trial …. Mesoblast need to keep things moving and adhere to their timeline for this indication’s trial (Q3 2023) …. outside of that I am expecting nothing more than a standard financial update for compliance purposes …… best not to expect much so you won’t be disappointed IMO


GLTAH